276 related articles for article (PubMed ID: 15761238)
1. The challenges of reliance on insulin-like growth factor I in monitoring disease activity in patients with acromegaly.
Paisley AN; Trainer PJ
Horm Res; 2004; 62 Suppl 1():83-8. PubMed ID: 15761238
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
[TBL] [Abstract][Full Text] [Related]
3. Disease activity in acromegaly may be assessed 6 weeks after discontinuation of pegvisomant.
Drake WM; Loureiro RA; Parkinson C; Monson JP; Besser GM; Trainer PJ
Eur J Endocrinol; 2005 Jan; 152(1):47-51. PubMed ID: 15762186
[TBL] [Abstract][Full Text] [Related]
4. The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly.
Parkinson C; Whatmore AJ; Yates AP; Drake WM; Brabant G; Clayton PE; Trainer PJ
Clin Endocrinol (Oxf); 2003 Aug; 59(2):168-74. PubMed ID: 12864793
[TBL] [Abstract][Full Text] [Related]
5. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
Higham CE; Atkinson AB; Aylwin S; Bidlingmaier M; Drake WM; Lewis A; Martin NM; Moyes V; Newell-Price J; Trainer PJ
J Clin Endocrinol Metab; 2012 Apr; 97(4):1187-93. PubMed ID: 22278424
[TBL] [Abstract][Full Text] [Related]
6. Clinical use of a growth hormone receptor antagonist in the treatment of acromegaly.
Drake WM; Parkinson C; Besser GM; Trainer PJ
Trends Endocrinol Metab; 2001 Nov; 12(9):408-13. PubMed ID: 11595543
[TBL] [Abstract][Full Text] [Related]
7. Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer International Metabolic Database).
Popovic V; Mattsson AF; Gaillard RC; Wilton P; Koltowska-Häggström M; Ranke MB
J Clin Endocrinol Metab; 2010 Sep; 95(9):4449-54. PubMed ID: 20610598
[TBL] [Abstract][Full Text] [Related]
8. Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly.
Trainer PJ; Drake WM; Perry LA; Taylor NF; Besser GM; Monson JP
J Clin Endocrinol Metab; 2001 Jul; 86(7):2989-92. PubMed ID: 11443156
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults.
Marzullo P; Di Somma C; Pratt KL; Khosravi J; Diamandis A; Lombardi G; Colao A; Rosenfeld RG
J Clin Endocrinol Metab; 2001 Jul; 86(7):3001-8. PubMed ID: 11443159
[TBL] [Abstract][Full Text] [Related]
10. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.
Trainer PJ; Drake WM; Katznelson L; Freda PU; Herman-Bonert V; van der Lely AJ; Dimaraki EV; Stewart PM; Friend KE; Vance ML; Besser GM; Scarlett JA; Thorner MO; Parkinson C; Klibanski A; Powell JS; Barkan AL; Sheppard MC; Malsonado M; Rose DR; Clemmons DR; Johannsson G; Bengtsson BA; Stavrou S; Kleinberg DL; Cook DM; Phillips LS; Bidlingmaier M; Strasburger CJ; Hackett S; Zib K; Bennett WF; Davis RJ
N Engl J Med; 2000 Apr; 342(16):1171-7. PubMed ID: 10770982
[TBL] [Abstract][Full Text] [Related]
11. [Pegvisomant--growth hormone receptor antagonist in the treatment of acromegaly].
Zgliczyński W; Zdunowski P
Endokrynol Pol; 2007; 58(5):408-16. PubMed ID: 18058736
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
[TBL] [Abstract][Full Text] [Related]
13. Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly.
Parkinson C; Drake WM; Wieringa G; Yates AP; Besser GM; Trainer PJ
Clin Endocrinol (Oxf); 2002 Mar; 56(3):303-11. PubMed ID: 11940041
[TBL] [Abstract][Full Text] [Related]
14. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
[TBL] [Abstract][Full Text] [Related]
15. Use of a GH receptor antagonist (GHRA) to explore the relationship between GH and IGF-I in adults with severe GH deficiency (GHD).
Berg CA; Pokrajac A; Bidlingmaier M; Strasburger CJ; Shalet SM; Trainer PJ
Clin Endocrinol (Oxf); 2009 Mar; 70(3):439-45. PubMed ID: 19067728
[TBL] [Abstract][Full Text] [Related]
16. Endogenous estradiol may influence IGF-I levels in acromegalic women treated with pegvisomant.
Roemmler J; Bidlingmaier M; Schopohl J
Pituitary; 2010; 13(1):89-93. PubMed ID: 18498055
[TBL] [Abstract][Full Text] [Related]
17. Findings and theoretical considerations on the usefulness of the acid-labile subunit in the monitoring of acromegaly.
Morrison KM; Wu Z; Bidlingmaier M; Strasburger CJ
Growth Horm IGF Res; 2001 Jun; 11 Suppl A():S61-3. PubMed ID: 11527090
[TBL] [Abstract][Full Text] [Related]
18. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal.
Parkinson C; Kassem M; Heickendorff L; Flyvbjerg A; Trainer PJ
J Clin Endocrinol Metab; 2003 Dec; 88(12):5650-5. PubMed ID: 14671148
[TBL] [Abstract][Full Text] [Related]
19. Pegvisomant: an advance in clinical efficacy in acromegaly.
Stewart PM
Eur J Endocrinol; 2003 Apr; 148 Suppl 2():S27-32. PubMed ID: 12670298
[TBL] [Abstract][Full Text] [Related]
20. Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men.
Veldhuis JD; Bidlingmaier M; Anderson SM; Wu Z; Strasburger CJ
J Clin Endocrinol Metab; 2001 Jul; 86(7):3304-10. PubMed ID: 11443205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
